Hydroxychloroquine in Untreated B-CLL Patients

Stopped early · Phase 2

Conditions studied: B-Cell Chronic Lymphocytic Leukemia

In brief

Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine 400mg po daily for up to one year. They will be monitored for disease status as well as adverse reactions after two weeks and then every 4 weeks. Ophthalmologic exams is required at baseline and every 6 months or sooner if the patient develops any visual disturbances.

Key facts

Study ID

NCT00771056

Run by

Northwell Health

People needed

23

Starts

2008-07-01

Expected to finish

2012-01-01

Last updated by the study team

2016-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Flow cytometry confirmed B-CLL
• No prior chemotherapy or immunotherapy
• Performance status 0-2
• Age > 18 years old
• If childbearing age, woman you must be willing to use birth control for length of hydroxychloroquine use
• Must have capacity to consent for study and sign consent form
• Asymptomatic CLL not requiring treatment at time of study entry

You may not qualify if…

• Pregnancy
• Significant optic nerve pathology as documented by an opthalmologic exam
• Hypersensitivity to 4-aminoquinoline compound
• Patients taking cardiac glycosides and cyclosporine

Where it is running

• Long Island Jewish Medical Center CLL Research and Treatment Center — New Hyde Park, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.